A Case Study on Epstein-Barr Virus Infection Induced Haemophagocytic Lymphohistiocytosis
Abstract
One of the effects of Epstein-Barr virus (EBV) infection is a condition known as Haemophagocytic Lymphohistiocytosis (HLH). Unrestrained immune system activation, which results in unrestricted cytokine release and macrophage activation, is the cause of the fatal uncommon condition known as HLH. EBV infection can cause systemic lymphadenopathy, cytopenia, and fulminant constitutional symptoms. Here, we have discussed a case of a 69-year-old man with neurological issues who also had HLH caused by EBV and beta cell lymphoma.
How to cite this article:
Gadhiya H P, Radhanpura Y V, Sanja S A, Parekh K, Jani B R. A Case Study on Epstein-Barr Virus Infection Induced Haemophagocytic Lymphohistiocytosis.Chettinad Health City Med J. 2024;13(1):99-101.
DOI: https://doi.org/10.24321/2278.2044.202417
References
Kim WY, Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. Epstein-Barr virus-associated T and NK-cell lymphoproliferative diseases. Front Pediatr. 2019 Mar 15;7:71. [PubMed] [Google Scholar]
Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987 May;61(5):1416-20. [PubMed] [Google Scholar]
Zhao A, Yang J, Li M, Li L, Gan X, Wang J, Li H, Shen K, Yang Y, Niu T. Epstein-Barr Virus-positive lymphomaassociated hemophagocytic syndrome: a retrospective, single-center study of 51 patients. Front Immunol. 2022 Apr 11;13:882589. [PubMed] [Google Scholar]
Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein–Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res. 2014 May;58(2-3):268-76. [PubMed] [Google Scholar]
La Rosée P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J, Girschikofsky M, Jordan MB, Kumar A, van Laar JA, Lachmann G, Nichols KE, Ramanan AV, Wang Y, Wang Z, Janka G, Henter JI. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019 Jun 6;133(23):2465-77. [PubMed] [Google Scholar]
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Apr 26;383(9927):1503-16. [PubMed] [Google Scholar]
Odumade OA, Hogquist KA, Balfour Jr HH. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011 Jan;24(1):193-209. [PubMed] [Google Scholar]
Vetsika EK, Callan M. Infectious mononucleosis and Epstein-Barr virus. Expert Rev Mol Med. 2004 Nov;6(23):1-6. [PubMed] [Google Scholar]
Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O’Connor N, Rowe M. Epstein-Barr virusassociated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis. 2010 Jul 1;51(1):66-9. [PubMed] [Google Scholar]
Goudarzipour K, Kajiyazdi M, Mahdaviyani A. Epstein-barr virus-induced hemophagocytic lymphohistiocytosis. Int J Hematol Oncol Stem Cell Res. 2013;7(1):42. [PubMed] [Google Scholar]
Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015 Jun;26(3):263-80. [PubMed] [Google Scholar]
Imashuku S. Clinical features and treatment strategies of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002 Dec;44(3):259-72. [PubMed] [Google Scholar]
